Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04124926
Other study ID # EE-301
Secondary ID 2019-002579-33
Status Completed
Phase Phase 3
First received
Last updated
Start date October 28, 2019
Est. completion date August 24, 2021

Study information

Verified date July 2022
Source Phathom Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the efficacy and safety of vonoprazan compared to lansoprazole in participants with erosive esophagitis.


Recruitment information / eligibility

Status Completed
Enrollment 1027
Est. completion date August 24, 2021
Est. primary completion date July 29, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. The participant is =18 years of age at the time of informed consent signing. 2. In the opinion of the investigator or subinvestigators, the participant is capable of understanding and complying with protocol requirements. 3. The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures. The participant is informed of the full nature and purpose of the study, including possible risks and side-effects. The participant has the ability to cooperate with the investigator. Ample time and opportunity should be given to read and understand verbal and/or written instructions. 4. The participant is found to have endoscopically confirmed EE of LA Classification Grades A to D during the Screening Period (Visit 1) as assessed by a central adjudicator. The target number of participants with LA classification Grade C or D will be approximately 30% of the total number of participants (300 total). Enrollment of EE participants with Grade A or B will end when the number of participants with Grade A or B EE is approximately 700 or 70% of the total planned number of participants. Given the invasive nature of an endoscopy, any endoscopic confirmation performed in a routine clinical setting before signing the informed consent will be acceptable to use for the purpose of fulfilling the screening requirement if all of the following apply: (1) appropriate endoscopy pictures were taken; (2) appropriate gastric biopsy samples were taken; (3) the endoscopy pictures can be sent to the central adjudicator via the adjudication systems; and (4) all screening procedures (including the completion of adjudication) AND randomization can be completed within a 7-day period after the date of the endoscopy. 5. A female participant of childbearing potential who is or may be sexually active with a nonsterilized male partner agrees to routinely use adequate contraception from the signing of informed consent until 4 weeks after the last dose of study drug. Exclusion Criteria: 1. The participant's endoscopic examination for entering this study fails to confirm EE within 7 days (no later than 10 days on rare occasion with sponsor approval) prior to randomization. 2. The participant is determined to be positive for Helicobacter pylori (HP) or has had an HP infection within 45 days of randomization. 3. The participant has endoscopic Barrett's esophagus (>1 cm of columnar-lined esophagus) and/or definite dysplastic changes in the esophagus. 4. The participant has any other condition affecting the esophagus, including eosinophilic esophagitis; esophageal varices; viral or fungal infection; esophageal stricture; a history of radiation therapy, radiofrequency ablation, endoscopic mucosal resection, or cryotherapy to the esophagus; or any history of caustic or physiochemical trauma (including sclerotherapy or esophageal variceal band ligation). However, participants diagnosed with Schatzki's ring (mucosal tissue ring around lower esophageal sphincter) are eligible to participate. 5. The participant has scleroderma (systemic sclerosis). 6. The participant has a history of surgery or endoscopic treatment affecting gastroesophageal reflux, including fundoplication and dilation for esophageal stricture (except Schatzki's ring) or a history of gastric or duodenal surgery (except endoscopic removal of benign polyps). 7. The participant has an active gastric or duodenal ulcer at the start of the Screening Period. Additionally, participants with gastric or duodenal erosions are permitted to participate. 8. The participant has received any investigational compound (including those in post marketing studies) within 30 days prior to the start of the Screening Period. A participant who has been screen failed from another clinical study and who has not been dosed may be considered for enrollment in this study. 9. The participant is a study site employee, an immediate family member, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (eg, spouse, parent, child, sibling) or who may have consented under duress. 10. The participant has cutaneous lupus erythematosus or systemic lupus erythematosus. 11. The participant has had clinically significant upper or lower gastrointestinal bleeding within 4 weeks prior to randomization. 12. The participant has Zollinger-Ellison syndrome or other gastric acid hypersecretory conditions. 13. The participant has a history of hypersensitivity or allergies to vonoprazan (including the formulation excipients: D-mannitol, microcrystalline cellulose, hydroxypropyl cellulose, fumaric acid, croscarmellose sodium, magnesium stearate, hypromellose, macrogol 8000, titanium oxide, or red or yellow ferric oxide), PPIs, or any excipients used in the 13C-urea breath test: mannitol, citric acid, or aspartame. Skin testing may be performed according to local standard practice to confirm hypersensitivity. 14. The participant has a history of alcohol abuse, illegal drug use, or drug addiction within the 12 months prior to screening, or regularly consumes >21 units of alcohol (1 unit = 12 oz/300 mL beer, 1.5 oz/25 mL hard liquor/spirits, or 5 oz/100 mL wine) per week based on self-report. Participants must have a negative urine drug screen at screening. 15. The participant is taking any excluded medications or treatments. 16. If female, the participant is pregnant, lactating, or intending to become pregnant before, during, or within 4 weeks after participating in this study; or intending to donate ova during such time period. 17. The participant has a history or clinical manifestations of significant central nervous system, cardiovascular, pulmonary, hepatic, renal, metabolic, other gastrointestinal, urological, endocrine, or hematological disease that, in the opinion of the investigator, would confound the study results or compromise participant safety. 18. The participant requires hospitalization or has surgery scheduled during the course of the study or has undergone major surgical procedures within 30 days prior to the Screening Visit. 19. The participant has a history of malignancy (including MALToma) or has been treated for malignancy within 5 years prior to the start of the Screening Period (Visit 1). (The participant may be included in the study if he/she has cured cutaneous basal cell carcinoma or cervical carcinoma in situ). 20. The participant has acquired immunodeficiency syndrome or human immunodeficiency virus infection, or tests positive for the hepatitis B surface antigen, hepatitis C virus (HCV) antibody, or HCV RNA. However, participants who test positive for HCV antibody but negative for HCV RNA are permitted to participate. 21. The participant has any of the following abnormal laboratory test values at the start of the Screening Period: 1. Creatinine levels: >2 mg/dL (>177 µmol/L) 2. Alanine aminotransferase or aspartate aminotransferase >2 × the upper limit of normal (ULN) or total bilirubin >2 × ULN.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Vonoprazan
Over-encapsulated tablet administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.
Lansoprazole
Over-encapsulated capsule administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.

Locations

Country Name City State
Bulgaria Multiprofile Hospital for Active Treatment Puls AD - PPDS Blagoevgrad
Bulgaria University Multiprofile Hospital for Active Treatment Pleven
Bulgaria Diagnostic-Consultative Center Aleksandrovska EOOD Sofia
Bulgaria Fourth Multiprofile Hospital for Active Treatment Sofia Sofia City
Bulgaria Medical Center Excelsior OOD - PPDS Sofia
Bulgaria Second Multiprofile Hospital for Active Treatment Sofia Sofia
Bulgaria Synexus - Medical Center Synexus Sofia EOOD Sofia
Bulgaria Synexus - Medical Centre Synexus Sofia EOOD Stara Zagora
Czechia PreventaMed s.r.o. Olomouc
Czechia Synexus Czech s.r.o. Prague
Czechia MEDIC KRAL s.r.o. Praha Prague
Czechia Krajska zdravotni, a.s. - Masarykova nemocnice v Usti nad Labem, o.z. Oddeleni gastroenterolgie Usti nad Labem
Czechia Nemocnice Pardubickeho kraje, a.s. Orlickoustecka nemocnice, Interni oddeleni, Cs. Usti nad Orlici Pardubice
Hungary Synexus (DRS) - Synexus Magyarország Kft. Budapest Budapest
Hungary Debreceni Egyetem Klinikai Kozpont Nagyerdei Krt. 98, Belgyogyaszati Klinika Debrecen Hajdú-Bihar
Hungary Synexus Affiliate - Synexus Magyarorszag Kft. Debrecen Debrecen
Hungary Synexus (DRS) - Synexus Magyarorszag Kft. Gyula Gyula
Hungary Synexus Affiliate BKS Research Kft. Hatvan Hatvan Heves
Hungary Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz Nyíregyháza Szabolcs-Szatmár-Bereg
Hungary Synexus (DRS) - Synexus Magyarország Kft. Zalaegerszeg Zalaegerszeg
Poland Gabinet Lekarski-Janusz Rudzinski ul. Powstancow Warszawy 5 Bydgoszcz
Poland Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy Centrum Endoskopii Zabiegowej - Poradnia Chorob Jelitowych Bydgoszcz
Poland Synexus - Czestochowa Czestochowa
Poland Synexus - Gdansk Gdansk
Poland Synexus - Gdynia Gdynia
Poland Synexus - Katowice Katowice
Poland Synexus Affiliate - Krakowskie Centrum Medyczne Kraków
Poland Centrum Opieki Zdrowotnej Orkan-Med Stec-Michalska Sp. J. Ksawerów
Poland Santa Familia Centrum Badan Profilaktyki i Leczenia Lódz
Poland Synexus - Lodz Lódz
Poland GASTRO MED Zaklad Opieki Zdrowotnej Lublin
Poland Synexus - Poznan Poznan
Poland Korczowski Bartosz, Gabinet Lekarski Rzeszów
Poland Twoja Przychodnia - Szczecinskie Centrum Medyczne Szczecin
Poland Gastromed Specjalistyczne Centrum Gastrologii i Endoskopii Torun
Poland REUMATIKA - Centrum Reumatologii NZOZ Warszawa
Poland Synexus - Warszawa Warszawa
Poland Melita Medical Wroclaw
Poland Synexus - Wroclaw Wroclaw
United Kingdom Synexus - Wales Clinical Research Centre Cardiff
United Kingdom Synexus - Lancashire Clinical Research Centre Chorley
United Kingdom Synexus - Midlands Clinical Research Centre Edgbaston West Midlands
United Kingdom CPS Research Glasgow
United Kingdom Synexus - Hexham Clinical Research Centre Hexham
United Kingdom Synexus - Merseyside Clinical Research Centre Liverpool
United Kingdom Synexus - Manchester Clinical Research Centre Manchester
United Kingdom Synexus Thames Valley Clinical Research Centre Reading Berkshire
United Kingdom Synexus - North Tees Clinical Research Centre Stockton-on-Tees
United States Anaheim Clinical Trials LLC Anaheim California
United States Synexus Clinical Research US, Inc. Anderson South Carolina
United States Pinnacle Research Group Anniston Alabama
United States North Alabama Research Center LLC Athens Alabama
United States Atlanta Gastroenterology Associates Atlanta Georgia
United States Nexgen Research Center Atlanta Georgia
United States Inquest Clinical Research Baytown Texas
United States Washington Gastroenterology Bellevue Washington
United States Synexus Clinical Research US, Inc. Birmingham Alabama
United States Gastroenterology Associates of Fairfield County Bridgeport Connecticut
United States Connecticut Clinical Research Foundation Bristol Connecticut
United States Synexus Clinical Research US, Inc. - East Valley Family Physicians, PLC Chandler Arizona
United States Clinical Trials of South Carolina Charleston South Carolina
United States Carolinas Research Center Charlotte North Carolina
United States New River Valley Research Institute Christiansburg Virginia
United States eStudySite - Chula Vista - PPDS Chula Vista California
United States GW Research, Inc. - ClinEdge - PPDS Chula Vista California
United States Iowa Digestive Disease Center Clive Iowa
United States Synexus Clinical Research US, Inc. - Colorado Springs Family Practice Colorado Springs Colorado
United States Kindred Medical Institute for Clinical Trials, LLC Corona California
United States Clinical Trials Management LLC Covington Louisiana
United States Synexus Clinical Research US, Inc. - Dallas Dallas Texas
United States Dayton Gastroenterology, Inc Dayton Ohio
United States Duke University Medical Center Durham North Carolina
United States Riverside Clinical Research Edgewater Florida
United States Texas Tech University Health Sciences Center El Paso El Paso Texas
United States MediSphere Medical Research Center, LLC Evansville Indiana
United States Verity Research, Inc. Fairfax Virginia
United States HB Clinical Trials, Inc. Fountain Valley California
United States Prestige Clinical Research Franklin Ohio
United States Medication Management LLC Greensboro North Carolina
United States Carolina Research Greenville North Carolina
United States Illinois Gastroenterology Group Gurnee Illinois
United States Drug Trials America - ClinEdge Hartsdale New York
United States Synexus Clinical Research US, Inc. Site 1 Henderson Nevada
United States Synexus Clinical Research US, Inc. Site 2 Henderson Nevada
United States Peters Medical Research, LLC - ClinEdge - PPDS High Point North Carolina
United States Research Centers of America - ERG Hollywood Florida
United States CroNOLA, LLC. Houma Louisiana
United States Biopharma Informatic, LLC Houston Texas
United States Precision Research Institute, LLC Houston Texas
United States Medical Affiliated Research Center Inc Huntsville Alabama
United States Nature Coast Clinical Research Inverness Florida
United States ENCORE Borland-Groover Clinical Research - ERN - PPDS Jacksonville Florida
United States Multi Specialty Clinical Research Johnson City Tennessee
United States The Alliance for Multispecialty Research, LLC Kansas City Missouri
United States OM Research LLC Lancaster California
United States Las Vegas - Site 1 Las Vegas Nevada
United States Sierra Clinical Research - ClinEdge - PPDS Las Vegas Nevada
United States Site 2 Las Vegas Nevada
United States Synexus Clinical Research US, Inc. Layton Utah
United States Applied Research Center of Little Rock Little Rock Arkansas
United States Preferred Research Partners - ClinEdge - PPDS Little Rock Arkansas
United States Torrance Clinical Research Institute Lomita California
United States LA County + USC Medical Center Los Angeles California
United States Southern California Research Institute Medical Group, Inc. Los Angeles California
United States Blue Ridge Medical Research Lynchburg Virginia
United States Gastroenterology Associates of Central Georgia, LLC Macon Georgia
United States Rio Grande Gastroenterology McAllen Texas
United States Synexus Clinical Research US, Inc. - Central Arizona Medical Associates, PC Mesa Arizona
United States Synexus Clinical Research US, Inc. - Desert Clinical Research, LLC Mesa Arizona
United States Clinical Trials Management LLC Metairie Louisiana
United States Columbus Clinical Services LLC Miami Florida
United States Jesscan Medical Research Miami Florida
United States Nuren Medical and Research Center Miami Florida
United States Premier Research Associate, Inc. Miami Florida
United States Facey Medical Foundation Mission Hills California
United States Coastal Carolina Research Center Mount Pleasant South Carolina
United States Clinical Research Associates Inc Nashville Tennessee
United States Vanderbilt University Medical Center Nashville Tennessee
United States Gastroenterology Health Partners, PLLC New Albany Indiana
United States Central Sooner Research Norman Oklahoma
United States Arkansas Gastroenterology North Little Rock Arkansas
United States Atria Clinical Research - BTC - PPDS North Little Rock Arkansas
United States Summit Digestive & Liver Disease Specialists State Street Clinic Oakbrook Terrace Illinois
United States Advanced Research Institute Ogden Utah
United States Heartland Clinical Research, Inc Omaha Nebraska
United States Southtowns Gastroenterology, PLLC Orchard Park New York
United States Gutierrez Medical Center Orlando Florida
United States Advanced Gastroenterology Associates, LLC Palm Harbor Florida
United States Palmtree Clinical Research Palm Springs California
United States Innovation Medical Research Center Palmetto Bay Florida
United States Digestive System Healthcare Pasadena Texas
United States In-Quest Medical Research, LLC Peachtree Corners Georgia
United States Pearland Physicians Pearland Texas
United States Elite Clinical Studies - Phoenix - BTC - PPDS Phoenix Arizona
United States Hope Research Institute LLC Phoenix Arizona
United States Synexus Clinical Research US, Inc. - St. Petersburg Pinellas Park Florida
United States Synexus Clinical Research US, Inc. Plano Texas
United States Carolina's GI Research, LLC Raleigh North Carolina
United States Rapid City Medical Center LLP Rapid City South Dakota
United States Advanced Research Institute Reno Nevada
United States Meridian Clinical Research Rockville Maryland
United States Washington University School of Medicine Saint Louis Missouri
United States Gastroenterology Research of San Antonio (GERSA) San Antonio Texas
United States Quality Research Inc San Antonio Texas
United States Southern Star Research Institute, LLC San Antonio Texas
United States Medical Associates Research Group, Inc. San Diego California
United States Precision Research Institute San Diego California
United States Paragon Rx Clinical, Inc. Santa Ana California
United States Harborview Medical Center, University of Washington Medical Center Seattle Washington
United States Louisiana Research Center, LLC Shreveport Louisiana
United States Precision Clinical Research, LLC Sunrise Florida
United States Guardian Angel Research Center Tampa Florida
United States Clinical Associates Research Towson Maryland
United States Oakland Medical Research Center Troy Michigan
United States Del Sol Research Management - BTC - PPDS Tucson Arizona
United States Western States Clinical Research, Inc. Wheat Ridge Colorado
United States Gastroenterology Associates of Western Michigan, PLC Wyoming Michigan

Sponsors (1)

Lead Sponsor Collaborator
Phathom Pharmaceuticals, Inc.

Countries where clinical trial is conducted

United States,  Bulgaria,  Czechia,  Hungary,  Poland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Healing Phase: Percentage of Participants Who Had Complete Healing of EE by Week 8 A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy. Week 8
Primary Maintenance Phase: Percentage of Participants Who Maintained Complete Healing of EE at Week 24 A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy. Week 24
Secondary Healing Phase: Percentage of 24-hour Heartburn-free Days A 24-hour heartburn-free day was defined as a day having no heartburn among all diary entries for that day. The percentage of 24-hour heartburn-free days was calculated using all days with at least 1 evening or morning diary entry during the treatment period of this phase. Day 1 to Week 8
Secondary Healing Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Had Complete Healing of EE at Week 2 A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy.
LA Classification of Esophagitis Grading Scale:
Grade C: One or more mucosal breaks that are continuous between the tops of 2 or more mucosal folds, which involves less than 75% of the circumference.
Grade D: One or more mucosal breaks, which involves at least 75% of the circumference.
Week 2
Secondary Healing Phase: Percentage of Participants With Onset of Sustained Resolution of Heartburn by Day 3 Sustained resolution was defined as at least 7 consecutive days with no daytime or night time heartburn as assessed by the daily diary. A participant was considered to have sustained resolution of heartburn by Day 3 if the first day of the 7 consecutive days without symptoms was on Days 1, 2, or 3. Day 1 to maximum of Day 10 (inclusive of 7 day heartburn assessment)
Secondary Healing Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Had Complete Healing of EE by Week 8 A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy.
LA Classification of Esophagitis Grading Scale:
Grade C: One or more mucosal breaks that are continuous between the tops of 2 or more mucosal folds, which involves less than 75% of the circumference.
Grade D: One or more mucosal breaks, which involves at least 75% of the circumference.
Week 8
Secondary Healing Phase: Percentage of Participants Who Had Complete Healing of EE at Week 2 A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy. Week 2
Secondary Maintenance Phase: Percentage of Participants With Baseline LA Classification Grades C or D Who Maintained Complete Healing of EE at Week 24 A participant was considered to have complete healing of EE if healing was demonstrated during endoscopy.
LA Classification of Esophagitis Grading Scale:
Grade C: One or more mucosal breaks that are continuous between the tops of 2 or more mucosal folds, which involves less than 75% of the circumference.
Grade D: One or more mucosal breaks, which involves at least 75% of the circumference.
Week 24
Secondary Maintenance Phase: Percentage of 24-hour Heartburn-free Days A 24-hour heartburn-free day was defined as a day having no heartburn among all diary entries for that day. The percentage of 24-hour heartburn-free days was calculated using all days with at least 1 evening or morning diary entry during the treatment period of this phase. Day 1 to Week 24
See also
  Status Clinical Trial Phase
Completed NCT01452776 - Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis Phase 3
Recruiting NCT05587309 - A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis Phase 3
Completed NCT01459367 - Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis Phase 3
Completed NCT00228527 - Esomeprazole for Treatment of GERD in Pediatric Patients Phase 4
Completed NCT01499368 - A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients Phase 3
Not yet recruiting NCT04613895 - Treatment Effect According to Timing of Administration of DWP14012 40 mg N/A
Recruiting NCT02615184 - A Study of Dexlansoprazole in Healing and Maintenance of Healed Erosive Esophagitis (EE) in Children Phase 2
Completed NCT02456935 - Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis Phase 3
Completed NCT02028663 - Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis Phase 2
Completed NCT03006874 - Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis Phase 3
Completed NCT02388724 - Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis Phase 3
Completed NCT01865825 - Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)? N/A
Completed NCT02679508 - Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety Phase 4
Recruiting NCT06391177 - A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily Phase 1
Completed NCT05050188 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008 Phase 1
Completed NCT01874535 - Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy Phase 4
Completed NCT00206180 - NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis Phase 4
Completed NCT01642615 - Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents Phase 2
Completed NCT01630746 - A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis Phase 3
Completed NCT01509261 - Efficacy Study of Ilaprazole to Treat Erosive Esophgitis Phase 3